Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Illumina Launches TruSight™ Tumor Content Set

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Enables somatic variant detection in solid tumors using next-generation sequencing (NGS).

Illumina, Inc. has announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

TruSight Tumor provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.

TruSight Tumor also offers a comprehensive NGS-based tumor profiling solution that provides a broader and more cost-effective view of tumor heterogeneity compared to genotyping-based methods.

Researchers can simultaneously detect somatic changes in multiple genes across the tumor genome, as referenced in industry guidelines, as well as emerging biomarkers implicated in pharmaceutical clinical trials.

Designed for use with formalin-fixed paraffin-embedded (FFPE) samples, TruSight Tumor enables high levels of sensitivity for minor allele detection (below 5%), with limited DNA input requirements.

“TruSight Tumor is designed to run on Illumina’s industry-leading sequencing platforms and enables clinical researchers to understand the molecular heterogeneity of FFPE tumor samples,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business.

Posard continued, “This technology has the potential to expand candidates for targeted therapies who may otherwise be missed with single variant or single gene approaches.”

“Tumor characterization using next-generation sequencing enables clinical research laboratories to gain a deeper understanding of underlying biology. In order to detect clinically relevant variants, it is important to look beyond single genes or hotspot mutations while achieving very low levels of sensitivity," said Dr. Robert Daber, Technical Director of Clinical Genomics, Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania.

TruSight Tumor is the first content set designed for somatic variant detection on the Illumina MiSeq® platform.

As a portfolio, TruSight content sets are designed for high performance targeted sequencing to meet the specific needs of the clinical research laboratory by providing high analytical sensitivity and specificity.

They offer exceptional performance in the capture and sequencing of targeted genomic regions, and are selected through collaborations with experts from leading institutions.

TruSight content sets are for research use only and not intended for diagnostic use. TruSight Tumor is now available for order with shipment expected in Q2’13.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Illumina Announces Strategic Collaboration with Merck Serono
Collaboration to expand companion diagnostics for oncology.
Friday, March 13, 2015
Illumina and Merck Serono Collaborate
Strategic collaboration will expand companion diagnostics for oncology.
Tuesday, March 10, 2015
Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates
Obtains commitment from viking global investors to advance genomics startups.
Friday, February 27, 2015
Illumina Q4 Revenues Up 32%
Illumina has announced its financial results for the fourth quarter and fiscal year 2014.
Wednesday, January 28, 2015
Scientific News
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.
Far-reaching Genetic Study of 1,000 UK People
300,000 gene variants from 1,000 people made publically available via F1000Research.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
Targeting DNA
Protein-based sensor could detect viral infection or kill cancer cells.
Genetic Sleuthing
Sabeti team applies Ebola methods to shed light on spread of Lassa fever.
Seeking “Gold Standard” Wastewater Treatments
Metagenomic analyses lend insights into how microbes break down wastewater contaminants.
Using Genetic Sequencing to Manage Cancer in Children
A team of scientists have investigated the feasibility of incorporating clinical sequencing information into the care of young cancer patients.
Big Data Tool to Reveal Immune System Role in Diseases
Researchers from the Icahn School of Medicine at Mount Sinai and Princeton University have designed a new online tool that predicts the role of key proteins and genes in diseases of the human immune system.
Next-Gen Genomic Tests Identify Brain-Eating Amoeba
New UCSF center aims to make tests more affordable and accessible to doctors.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos